Deudextromethorphan hydrobromide hydrate

Deudextromethorphan (AVP-786) hydrobromide hydrate is a deuterated form of dextromethorphan/quinidine (AVP-923, Nuedexta). Deudextromethorphan hydrobromide hydrate, a glutamate-targeting agent, is an orally active N-methyl-D-aspartate (NMDA) receptor antagonist. Deudextromethorphan hydrobromide hydrate can be used for the research of Pseudo-Bulbar Affect, traumatic brain injury, behavioral disinhibition and agitation in AD[1][2][3].

Signaling Pathways >> Neuronal Signaling >> iGluR

Research Areas >> Neurological Disease

Signaling Pathways >> Membrane Transporter/Ion Channel >> iGluR

[1]. Khoury R, et al. AVP-786 as a promising treatment option for Alzheimer's Disease including agitation. Expert Opin Pharmacother. 2021 May;22(7):783-795.

[2]. Garay RP, et al. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type. Expert Opin Investig Drugs. 2017 Jan;26(1):121-132.

[3]. Hecking J, et al. Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders. Chronic Stress (Thousand Oaks). 2021 Jun 2;5:24705470211020446.